To print: Select File and then Print from your browser's menu

Title: Topical Alprostadil Appears Effective in Female Sexual Dysfunction: Presented at AUA

"Topical Alprostadil Appears Effective in Female Sexual Dysfunction: Presented at AUA"

By Ed Susman Special to DG News ORLANDO, FL -- May 28, 2002 -- A droplet of fluid containing alprostadil appears to relieve symptoms of female sexual dysfunction while improving sexual desire, genital sensation and sexual satisfaction, doctors reported here Monday at the 97th annual meeting of the American Urological Association. The treatment could provide the first drug therapy for female sexual dysfunction, said Marc Gittelman, MD, lead investigator of the study, from South Florida Medical Research, in Aventura, Florida. For their placebo-controlled, randomized multi-center study, Dr. Gittelman and colleagues recruited 78 women, mean age 55 years, to test topical alprostadil, dispensed by an eyedropper into the female genitalia. Sixty-seven percent of the women were postmenopausal and the remainder had either received a hysterectomy or bilateral oophorectomy. Dr. Gittelman said that the women filled out questionnaires designed to determine if they suffer from sexual dysfunction. "These questionnaires have been scientifically validated," he said. Half the women received the drug in the liquid vehicle; the other women received placebo. The women in the alprostadil group were given either a 100 ľg dose or a 400 ľg dose. The "no touch" study was performed in doctors' offices. The women watched erotic films and then applied the fluid to the clitoris and allowed it to spread to the surrounding tissues. The women reported feelings of genital warmth, sexual arousal and sexual satisfaction that were more significantly more intense if they received the higher dose of alprostadil than if they received placebo, said co-author Col. Raymond Costabile, MD, chief of urology service at Madigan Army Medical Center, Tacoma, Washington. There was no difference in responses between postmenopausal women and women who had undergone hysterectomy/oophorectomy. Dr. Gittelman said some of the women reported experiencing orgasm, despite the clinical nature of the study. He said further studies in which the drug will be used at home in situations involving sexual intercourse will determine if the drug works as expected. "This area of female sexual dysfunction is just exploding," said Dr. Wayne Hellstrom, professor of urology at Tulane University, in New Orleans, Louisiana. "It is something that we don't have any treatment for, and this drug does look promising." Dr. Costabile said adverse side effects were few and generally well-tolerated. Some women reported feeling uncomfortable burning sensations, but those sensations lasted less than a minute, he said. The study was sponsored by Vivus, of Mountain View, California, developer of topical alprostadil.

Copyright Š 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.